---
title: "Pembrolizumab - Non-Small Cell Lung Cancer (Pd-L1 Expression Positive)"
sidebar: mydoc_sidebar
permalink: db09037-mesh-d002289-1.html
toc: false 
---


Path ID: `DB09037_MESH_D002289_1`
{% include image.html url="images/db09037-mesh-d002289-1.png" file="db09037-mesh-d002289-1.png" alt="db09037-mesh-d002289-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/DB:DB09037">DB:DB09037 </a> | Pembrolizumab | Drug |
| <a href="https://identifiers.org/UniProt:Q15116">UniProt:Q15116 </a> | Programmed cell death protein 1 | Protein |
| <a href="https://identifiers.org/GO:0042098">GO:0042098 </a> | T cell proliferation | BiologicalProcess |
| <a href="https://identifiers.org/GO:0042110">GO:0042110 </a> | T cell activation | BiologicalProcess |
| <a href="https://identifiers.org/GO:0002424">GO:0002424 </a> | T cell mediated immune response to tumor cell | BiologicalProcess |
| <a href="https://identifiers.org/MESH:D002289">MESH:D002289 </a> | Non-small cell lung cancer (PD-L1 expression positive) | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Pembrolizumab | DECREASES ACTIVITY OF | Programmed Cell Death Protein 1 |
| Programmed Cell Death Protein 1 | NEGATIVELY REGULATES | T Cell Proliferation |
| Programmed Cell Death Protein 1 | NEGATIVELY REGULATES | T Cell Activation |
| T Cell Proliferation | POSITIVELY CORRELATED WITH | T Cell Mediated Immune Response To Tumor Cell |
| T Cell Activation | POSITIVELY CORRELATED WITH | T Cell Mediated Immune Response To Tumor Cell |
| T Cell Mediated Immune Response To Tumor Cell | NEGATIVELY CORRELATED WITH | Non-Small Cell Lung Cancer (Pd-L1 Expression Positive) |
|---------|-----------|---------|

Comment: Pembrolizumab is indicated for first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression [(Tumor Proportion Score (TPS) â‰¥50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations

Reference: 
  - [https://go.drugbank.com/drugs/DB09037#BE0003436](https://go.drugbank.com/drugs/DB09037#BE0003436)
  - [https://en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors](https://en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors)
